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Abstract
Background Apremilast, an oral phosphodiesterase (PDE) 4 inhibitor, has demonstrated efficacy in psoriasis, while its effi-
cacy in atopic dermatitis (AD) was found to be modest. AD is a chronic inflammatory skin disease associated with activation 
of T helper (Th) 2 and Th17 immunity and a compromised epidermal barrier.
Objective The objectives of this study were to examine the expression of PDE4 isoforms in skin from healthy subjects and 
AD patients, and to determine the effects of apremilast on AD-related inflammatory markers in vitro and in murine models 
of AD.
Methods The expression of PDE4 isoforms (A, B, C, and D) in skin biopsies from healthy subjects and AD patients was 
evaluated using immunohistochemistry and digital image analysis. Using quantitative real-time reverse-transcriptase poly-
merase chain reaction, we evaluated the effects of apremilast on gene expression in adult human epidermal keratinocytes 
(HEKa) stimulated by Th2 and Th17 cytokines, and in two mouse models of antigen-induced AD.
Results Expression of PDE4 isoforms increased up to three-fold in the epidermis of AD patients versus healthy skin. In 
interleukin (IL)-4 and IL-17-stimulated HEKa cells, apremilast significantly changed the expression of ILs, including IL-12/
IL-23p40 and IL-31, and alarmins S100A7, S100A8, and S100A12. In mouse models of AD, apremilast significantly reduced 
ear swelling and monocyte chemoattractant protein-1 expression.
Conclusion PDE4 is overexpressed in AD skin compared with normal skin, and inflammatory gene expression by human 
keratinocytes and mouse dermatitis can be modulated by apremilast.
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Key Points 
In the atopic dermatitis (AD) epidermis, phosphodiester-
ase (PDE) 4 isoform expression is increased up to three-
fold compared with healthy skin.
PDE4 inhibition with apremilast significantly changed 
messenger RNA expression of several interleukins (ILs), 
alarmins, and small proline-rich protein, in IL-4- and IL-
17-stimulated adult human epidermal keratinocyte cells.
In mouse models of AD, apremilast significantly reduced 
ear swelling and monocyte chemoattractant protein-1 
protein expression.
Results highlight the potential direct effects and limita-
tions of PDE4 inhibition on keratinocyte responses in 
AD.
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1 Introduction
Atopic dermatitis (AD), also known as atopic eczema, is 
an inflammatory, chronically relapsing skin disease [1] 
that is often associated with other atopic diseases [2–4]. 
AD typically begins in early childhood, generally before 
2 years of age, and often persists into adulthood. Epider-
mal barrier defects (e.g., filaggrin [FLG] mutations) and 
an altered immune response, both innate and adaptive, are 
core pathophysiological features in patients with AD [1]. 
The rapid innate immune response is mediated by several 
receptors that are expressed in keratinocytes and antigen-
presenting cells and are thought to prevent microbial replica-
tion [5]. Stimulation of these immune receptors by microbes 
or through tissue injury leads to the release of antimicro-
bial peptides, cytokines, and chemokines that enhance the 
strength of tight junctions to limit penetration of allergens 
and microbes. Studies have demonstrated that patients with 
AD have reduced production of keratinocyte-derived anti-
microbial peptides, which are needed to control infection 
by Staphylococcus aureus and viruses [5]. Therefore, these 
patients may be predisposed to microbial colonization and 
chronic skin inflammation.
Allergic inflammation also significantly reduces the 
antimicrobial peptide response in these patients, which may 
increase the risk of skin infection [5, 6]. Moreover, in the 
epidermis, Langerhans cells are thought to play a critical role 
in the initiation of allergic inflammation, which ultimately 
results in the activation of specific T cells with expression 
of T helper (Th) 2 cytokines (interleukin [IL]-4, IL-13, and 
IL-5) [7, 8], especially in the acute lesions. In contrast, Th1 
cytokines play a key role in chronic lesions [2]. Evidence 
from recent research also supports a role for IL-22 and a 
modest role for IL-17, including IL-17-related genes (i.e., 
CXCL1, CXCL2, P13, IL-23p19/IL-23A, and S100A12), in 
the disease progression of AD [9–11].
Cyclic adenosine monophosphate (cAMP) is a pivotal 
secondary messenger that results in the inhibition of the 
synthesis and release of pro-inflammatory mediators and 
cytokines [12]. cAMP and cyclic guanosine monophosphate 
are degraded through the activity of the large superfamily of 
phosphodiesterase (PDE) isoenzymes (1–11) [13]. Within 
this group, enzymes of the four-gene PDE4 family play a 
key role in degrading cAMP in inflammatory cells as well as 
in endothelial cells, smooth muscle cells, and keratinocytes 
[14, 15]. More than 20 splice variants are encoded by the 
PDE4A, PDE4B, PDE4C, and PDE4D genes due to dif-
ferential messenger RNA (mRNA) splicing [14, 16]. PDE4 
isoforms display a differential expression pattern in human 
testis, skeletal muscle, lung, and brain [17–19]. The over-
expression of PDE4 isoforms in the dermis and blood of pso-
riasis patients has previously been reported [20]. However, 
the expression patterns of PDE4 isoforms have not been 
described in the epidermis of patients with AD. An earlier 
study has demonstrated that PDE activity was increased in 
mononuclear leukocytes from patients with AD [21]. Inhibi-
tors of PDE4 elevate intracellular cAMP levels, which then 
inhibit a broad range of pro-inflammatory mediators, with 
activities in vitro and in preclinical models of asthma, lung 
neutrophilia, arthritis, inflammatory bowel disease, multiple 
sclerosis, osteoporosis, and other disease states [22–27].
Apremilast is a novel, orally administered, small-mole-
cule PDE4 inhibitor approved for treatment of adult patients 
with psoriatic arthritis, patients with moderate to severe 
plaque psoriasis, and patients with oral ulcers associated 
with Behçet’s syndrome [20, 28]. By inhibiting PDE4, apre-
milast elevates intracellular cAMP levels and thus down-reg-
ulates the inflammatory response by modulating expression 
of a network of pro-inflammatory mediators such as tumor 
necrosis factor-α, IL-23, and IL-17 [25, 29, 30]. Apremilast 
can also increase anti-inflammatory mediators such as IL-10 
and the IL-1 receptor antagonist in psoriasis and psoriatic 
arthritis patients [29, 31].
There are multiple models of AD in the mouse, using 
various antigens such as fluorescein isothiocyanate (FITC) 
[32] and dinitrochlorobenzene (DNCB) [33]. These models 
rely on a sensitization period wherein the antigen is applied 
directly to the skin of the abdomen or flank to allow dendritic 
cells to process and present the antigen to reactive T cells, 
which clonally expand and produce Th2 and Th17 cytokines 
and chemokines. This sensitization period is followed by an 
antigenic challenge period during which the same antigen 
is then applied to the ears on 1 or more days. The immune 
response can be gauged by measuring the ear thickness 
using calipers, and by isolating proteins from ear tissue 
homogenate to measure cytokine and chemokine levels. 
For example, the FITC model is characterized by elevated 
expression of IL-1β, IL-4, IL-5, IL-6, IL-13, IL-17, eotaxin, 
monocyte chemoattractant protein (MCP)-1/chemokine 
(C–C motif) ligand (CCL)-2, macrophage inflammatory 
protein (MIP)-1α/CCL4, RANTES (Regulated on Activa-
tion, Normal T Cell Expressed and Secreted), and thymus 
and activation-regulated chemokine (TARC) in the ear tissue 
[32]. AD therapeutics have been successfully tested in these 
models. For example, the mouse DNCB model has been 
used to demonstrate efficacy of systemically administered 
ciclosporin (cyclosporine A) [34]. DNCB has also been used 
as an antigen applied to the skin of healthy human volunteers 
to demonstrate the clinical efficacy of topical corticosteroids 
clobetasol propionate 0.05% versus betamethasone valerate 
0.1% [35].
The goals of these studies were to (a) assess the expres-
sion of PDE4 isoforms in the epidermis of healthy subjects 
and patients with AD; (b) determine the direct effects of 
PDE4 inhibition on Th2 (IL-4)- and Th17 (IL-17)-induced 
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gene expression in primary adult human epidermal keratino-
cytes (HEKa); and (c) assess the effects of apremilast in two 
mouse models of AD using two antigens, FITC [32] and 
DNCB [33].
2  Materials and Methods
2.1  Immunohistochemistry
Immunohistochemistry was used to evaluate the expression 
of PDE4 isoforms in human skin. Archived skin biopsies 
(4% buffered, formalin fixed and paraffin embedded) from 
three healthy subjects and five AD patients were used for the 
analysis. Tissue sections (4 μm) were cut and deparaffinized 
in xylene and rehydrated in graded alcohol. The slides were 
first boiled in citrate buffer, pH 6, for 20 min in a standard 
pressure cooker. For PDE4A and CD1a expression, slides 
were incubated with hydrogen peroxidase block for 5 min at 
room temperature, as indicated by the datasheet. All slides 
were incubated with ultra V block for 5 min at room temper-
ature to block non-specific background staining. After that, 
expression of PDE4A, PDE4B, PDE4C, and PDE4D were 
examined immunohistochemically by incubating the samples 
for 1 h at room temperature with the following antibodies: 
PDE4A antibody (1:100; ProteinTech Group Inc., Chicago, 
IL, USA), PDE4B (1:100; Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA), PDE4C (1:100; Santa Cruz Bio-
technology, Inc.), and PDE4D (1:100; Santa Cruz Biotech-
nology, Inc.) and CD1a (ready to use, Roche Diagnostics, 
Ventana, Tucson, AZ, USA). After three 5-min washes in 
phosphate-buffered saline (PBS), slides were incubated with 
secondary antibody for 45 min at room temperature followed 
by incubation with naphtol phosphate substrate for 10 min 
for PDE4B, PDE4C, and PDE4D detection, as suggested by 
the datasheet (Lab Vision Corporation, Fremont, CA, USA). 
For both PDE4A and CD1a expression, slides were incu-
bated with streptavidin peroxidase for 5 min at room temper-
ature. After four 5-min washes in PBS, slides were incubated 
with ready-to-use aminoethyl carbazole (AEC) Single Solu-
tion for 10 min as suggested by the datasheet (Lab Vision 
Corporation). Negative controls were obtained by omitting 
the primary antibody. The expression intensity was quanti-
tatively determined using ImageJ software (Wayne Rasband, 
National Institute of Mental Health, Bethesda, MD, USA). 
Total positive pixels were compared with healthy skin total 
positive pixels, which were indicated as 1.
2.2  Human Primary Adult Keratinocyte Cultures
Primary HEKa (ScienCell Research Laboratories, Carlsbad, 
CA, USA) were thawed, cultured in a T75 flask containing 
KGM™ Gold medium plus supplements for human cells 
(15 mL; Lonza, Walkersville, MD, USA) and incubated in 
5%  CO2 at 37 °C. The cells were cultured for 4–6 days (90% 
confluence) with media replenishment after the first 24 h. 
Upon achieving confluence, the media was removed; the 
cell monolayer was rinsed with PBS and trypsinized (1 mL 
of 0.05% trypsin). Fetal bovine serum (10 mL) was added 
after 5–10 min and the cells were centrifuged (Eppendorf 
Centrifuge 5810R) at 1200 rpm (Rotor A-4-81) for 5 min 
(Eppendorf AG, Hamburg, Germany). The cell pellet was 
rinsed in PBS, then re-suspended in fresh medium. Cells 
were then plated in six well plates and incubated for 4–6 h 
in 5%  CO2 at 37 °C to allow attachment and grown until they 
were 80–90% confluent. Cells were serum-starved overnight.
Apremilast (1.5 µM) or dimethyl sulfoxide (DMSO) was 
added and plates were incubated in 5%  CO2 at 37 °C for 
1 h. IL-4 (10 μg) was suspended in 100 μL of PBS contain-
ing 0.05% bovine serum albumin for a final concentration 
of 1 mg/mL. IL-17a (25 μg) was re-suspended in 250 μL 
of PBS containing 0.05% bovine serum albumin for a final 
concentration of 1 mg/mL. A 10 μg/mL stock was made by 
diluting 10 μL of IL-4 or IL-17a into 990 μL media. For a 
final concentration of 10 ng/mL, 5 μL of diluted IL-4 was 
added to the cells. For 50 ng/mL IL-17a final concentration, 
25 μL of diluted stock was added to the cells. Plates were 
incubated for 24 h in 5%  CO2 at 37 °C. Cells were washed 
with cold PBS and then 350 μL RLT buffer (Qiagen, Valen-
cia, CA, USA; catalog #79216) was added to each sample. 
A concentration of 1.5 μM of apremilast was selected for the 
HEKa experiments because it is equivalent to the apremilast 
30 mg twice daily clinical maximum concentration (Cmax) of 
670 ng/mL, based on a molecular weight of 460.5 [28, 36].
2.3  Quantitative Real‑Time Reverse‑Transcriptase 
Polymerase Chain Reaction
Expression of the following AD-related genes was measured 
by quantitative real-time reverse-transcriptase polymerase 
chain reaction (RT-PCR): IL-12B, IL-23A, and IL-19; CCL5, 
CCL17, and CCL18; pruritus mediators IL-31 and IL-33; 
terminal differentiation markers FLG, loricrin, periplakin, 
and small proline-rich protein 1A (SPRR1A); keratin 16; 
alarmins S100A7, S100A8, and S100A12; and defensin 
DEFB4B. Lysates were harvested for total RNA preparation 
with a QIAcube RNA extraction instrument (Qiagen, Valen-
cia, CA, USA) using QIAGEN  RNeasy® mini spin-column 
kits (catalog #74104). Purified RNA was reverse transcribed 
into complementary DNA with a thermal cycler (Life Tech-
nologies, Grand Island, NY, USA) using the reverse-tran-
scriptase kit (Life Technologies). The gene expression assay 
was carried out using the ViiA™ 7 RT-PCR system (Life 
Technologies) in triplicate. A glyceraldehyde 3-phosphate 
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dehydrogenase gene expression assay control was run for 
each sample and used as a normalization control.
Data are expressed as relative gene expression or relative 
quantification, where fold increase was defined as 2-ddCt 
(2-delta delta cycle threshold values). Relative quantification 
values were normalized to stimulation controls (DMSO). 
Significance versus the DMSO control was calculated using 
multiple two-tailed Student’s t tests using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla, CA, USA).
2.4  Mouse Models of Atopic Dermatitis
Balb/c mice were sensitized to antigens by applying either 
DNCB (n = 40) or FITC (n = 40) to the flanks on days 0 and 5. 
From day 6 through day 12, mice received orally either vehicle 
(carboxy-methylcellulose and  Tween® 80 [Sigma-Aldrich, St 
Louis, MO, USA] in sterile water; n = 10), apremilast 2.5 mg/kg 
twice daily (n = 10), apremilast 5 mg/kg twice daily (n = 10), 
or dexamethasone 1 mg/kg once daily (n = 10). The apremilast 
doses of 2.5 and 5 mg/kg twice daily were selected to repre-
sent doses that are 50% and 100% of the no observed adverse 
effect level of 10 mg/kg/day, as determined in a 6-month mouse 
toxicology study [37]. Apremilast was dissolved in vehicle and 
administered in a volume of 5 mL/kg. Dexamethasone was dis-
solved in ethanol and PBS and administered in a volume of 
10 mL/kg. On days 10, 11, and 12, antigens were applied to 
both ears. Thickness was measured on both ears by a digital 
caliper on days – 1 (baseline), 5 (prior to sensitization), 10, 11, 
12, and 13 when the animals were euthanized and the left ear 
was homogenized and the protein levels of IL-22, IL-4, IL-10, 
IL-13, IL-17A, MCP-1, RANTES, IL-12p40, and IL-23 were 
measured using the  Luminex® Assay.
Experiments were performed by MD Biosciences (St. 
Paul, MN, USA) following approval of an application sub-
mitted to the Committee for Ethical Conduct in the Care and 
Use of Laboratory Animals that stated the study complied 
with the rules and regulations set forth by the committee. 
Data were expressed as mean ± standard error of the mean 
(SEM) and were analyzed with one-way analysis of variance 
followed by Tukey’s test (GraphPad). P ≤ 0.05 represented 
a significant difference.
3  Results
3.1  All Phosphodiesterase 4 Isoforms are 
Up‑Regulated in the Epidermis from Patients 
with Atopic Dermatitis
In skin biopsies from healthy subjects, PDE4A was 
expressed in both the epidermal and dermal compartments. 
In the epidermis, expression in keratinocytes was strongest 
at the cytoplasmic level in the high spinous and granular 
layers. Scattered dermal cells were also strongly positive for 
PDE4A (Fig. 1). PDE4A staining was increased in AD com-
pared with healthy skin. PDE4A was markedly expressed 
at the cytoplasmic level in all epidermal suprabasal layers, 
particularly in the highest spinous layers.
In skin from healthy subjects, PDE4B was only expressed 
in dermal cells, with no expression in the epidermis. In skin 
biopsies from patients with AD, PDE4B staining was mostly 
negative in the epidermal compartment, except for intra-epi-
dermal dendritic cells where PDE4B was markedly expressed 
at the cytoplasmic level. In consecutive sections, similar cell 
types were also positive for CD1a staining, a marker for 
Langerhans cells, strongly suggesting that these dendritic 
cells express PDE4B (Fig. 1). PDE4C staining was negative 
in all layers of the epidermal compartment in skin biopsies 
from healthy subjects. In skin biopsies from patients with 
AD, PDE4C staining was observed in both the epidermis and 
dermis, and weakly expressed in keratinocytes of the spinous 
layer at the membrane level. PDE4C was also expressed in 
epidermal dendritic cells, similarly to cell types positive for 
CD1a and PDE4B in consecutive sections, suggesting that 
Langerhans cells may also express PDE4C (Fig. 1).
In skin from healthy subjects, PDE4D staining was nega-
tive in all epidermal layers from abdominal skin (not shown). 
However, in biopsies obtained from foreskin, PDE4D 
expression was weakly positive in basal keratinocytes at the 
cytoplasmic level (Fig. 1). In skin biopsies from patients 
with AD, PDE4D staining was higher in abdominal skin 
than in foreskin. Basal and suprabasal keratinocytes were 
PDE4D positive at the cytoplasmic level.
Relative to healthy subjects, the expression intensity of 
all PDE4 isoforms was significantly increased in the epider-
mis by 2.49- to 3.10-fold in patients with AD. Additionally, 
PDE4D was also significantly increased in the dermis by 
2.79-fold in patients with AD (Fig. 1).
3.2  Apremilast Normalizes Gene Expression 
of Inflammatory Mediators in Adult Human 
Epidermal Keratinocytes
IL-4 stimulation significantly (P < 0.05) increased gene 
expression of IL-19 (25-fold), IL-33 (2.5-fold), IL-31 (2.3-
fold), CCL5 (2.3-fold), CCL18 (two-fold), IL-12B (1.7-fold), 
and KRT16 (1.2-fold) in human adult epithelial keratino-
cytes. Conversely, IL-4 stimulation significantly (P < 0.05) 
decreased gene expression of DEFB4B (two-fold), IVL (2.4-
fold), and CCL17 (3.4-fold). In IL-4-stimulated keratino-
cytes, apremilast significantly inhibited IL-12/IL-23p40, 
IL-31, CCL5, FLG, SPRR1, S100A7, S100A8, and S100A12 
gene expression, and attenuated the inhibitory effect of IL-4 
on CCL17 gene expression (Fig. 2a).
IL-17 significantly (P < 0.05) increased gene expression 
of DEFB4 (200-fold), IL-19 (23-fold), S100A12 (13-fold), 
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S100A7 (seven-fold), S100A8 (five-fold), IL-23a (five-fold), 
CCL17 (2.7-fold), CCL18 (1.9-fold), IL-33 (1.7-fold), IL-
12/IL-23p40 (1.4-fold), IL-31 (1.3-fold), and SPRR1A 
(1.1-fold). IL-17 significantly (P < 0.05) decreased gene 
expression of loricrin (1.42-fold) and FLG (two-fold). In 
IL-17-stimulated keratinocytes, apremilast significantly 
inhibited IL-12/IL-23p40, IL-19, IL-31, IL-33, loricrin, 
SPRR1, S100A7, S100A8, and S100A12 gene expression, 
and increased CCL18 gene expression (Fig. 2b).
3.3  Apremilast Reduces Ear Swelling in Mouse 
Models of Dermatitis
Apremilast (2.5 and 5  mg/kg twice daily) signifi-
cantly reduced ear swelling in two models of dermatitis 
(Fig. 3). In the FITC model, ear thickness significantly 
(P < 0.05) increased from 0.19 ± 0.00 mm (baseline) to 
0.50 ± 0.02 mm (day 13) in vehicle-treated mice. Dexa-
methasone 1 mg/kg significantly reduced ear thickness to 
0.34 ± 0.01 mm on days 11–13 compared with vehicle-
treated mice (P < 0.05). Similarly, apremilast 2.5 and 5 mg/
kg significantly reduced ear thickness to 0.40 ± 0.01 mm 
and 0.41 ± 0.01 mm, respectively, on days 11–13 compared 
with vehicle-treated mice (P < 0.05).
In the DNCB model, ear thickness significantly 
(P < 0.05) increased from 0.21 ± 0.00 mm (baseline) to 
0.43 ± 0.01 mm (day 13) in vehicle-treated mice. Dexa-
methasone significantly (P < 0.05) decreased ear swell-
ing to 0.29 ± 0.00 mm on days 11–13 compared with 
vehicle-treated mice. Apremilast 2.5 and 5 mg/kg also 
significantly reduced ear thickness to 0.37 ± 0.01 mm 
and 0.39 ± 0.01 mm on days 11 and 13, respectively, 
Fig. 1  Expression and quantitative assessment of phosphodiesterase 
(PDE) 4 isoform protein levels in epidermal skin from patients with 
atopic dermatitis (AD). PDE4A, PDE4B, PDE4C, PDE4D, and CD1a 
in epidermal and dermal layers from healthy controls and patients 
with AD were detected with immunohistochemistry. Total positive 
pixels in the epidermis and dermis from patients with AD were com-
pared to total positive pixels from healthy subjects. The measured 
fold increase in PDE4 isoform expression in patients with AD relative 
to healthy controls is given. *P < 0.05, paired Student’s t test
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compared with vehicle-treated mice on day 13 (P < 0.05) 
(Fig. 3).
3.4  Apremilast Decreases Cytokine Protein Levels 
in Dinitrochlorobenzene‑Induced Dermatitis 
in Mice
MCP-1 protein levels in the inf lamed ear were 
184.21 ± 32.54 pg/mg in vehicle-treated mice. Apre-
milast significantly reduced MCP-1 protein levels to 
87.58 ± 18.04 pg/mg compared with vehicle (P < 0.05). 
There were trends toward a decrease by apremilast of 
IL-4, IL-10, IL-13, IL-17A, and IL-12/23p40 protein 
levels in the inflamed ears (Fig. 4).
4  Discussion
These results indicate that the expression of PDE4 iso-
forms is increased up to three-fold in the epidermis of 
patients with AD relative to healthy controls. PDE4 over-
expression in AD dermis was previously found to be simi-
lar to PDE4 overexpression in psoriatic dermis, although 
there were subtle differences between the two diseases, 
with the AD dermis expressing slightly higher levels of 
PDE4D and the psoriatic dermis expressing higher levels 
of PDE4A [20]. In the current study, the AD epidermis 
displayed a PDE4B and PDE4C expression pattern that 
resembled that of CD1a, a marker of Langerhans cells, 
suggesting that these dendritic cells express both PDE4B 
and PDE4C. In contrast, AD keratinocytes expressed 
PDE4A and PDE4D. The PDE4A expression pattern was 
predominantly epidermal in AD skin, while the PDE4D 
expression pattern was both epidermal and dermal. In 
primary human epidermal keratinocytes stimulated with 
either IL-4 or IL-17, PDE4 inhibition with apremilast sig-
nificantly reduced mRNA expression of IL-12/IL-23p40, 
the itch cytokine IL-31, SPRR1, and the alarmins S100A7, 
S100A8, and S100A12. Finally, in both mouse models of 
dermatitis, apremilast significantly reduced ear swelling 
and MCP-1 protein expression.
Langerhans cells play a critical role in AD, in both mice 
and humans. For instance, Langerhans cells penetrate the 
tight junctions that separate the stratum corneum from the 
stratum granulosum in human AD skin [38, 39]. A recent 
preclinical study [40] indicated that mice deficient in mye-
loid differentiation primary response gene 88 (MYD88) had 
Fig. 2  Effect of apremilast on interleukin (IL)-4- and IL-17-stimu-
lated adult human epidermal keratinocytes (HEKa). a IL-4-stimu-
lated HEKa; b IL-17A-stimulated HEKa. Data are expressed as the 
mean ± standard error of the mean, relative to IL-4 or IL-17 control, 
from three normal human keratinocyte cells, each tested in triplicate. 
RQ relative quantification, *P  <  0.05, **P  <  0.01, ***P  <  0.001, 
****P < 0.0001 vs. IL-4 or IL-17 control by paired Student’s t tests
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reduced epidermal thickening and diminished accumulation 
of macrophages within the inflamed skin. In addition, these 
mice had impaired emigration of Langerhans cells out of 
the epidermis. A separate study demonstrated that patients 
with AD had significantly higher production of both CCL17 
and CCL22 monocyte-derived Langerhans cells than healthy 
controls [39]. These recent published data are consistent 
with our results obtained in mouse models of dermatitis.
Inhibition of PDE4 elevates intracellular cAMP lev-
els, which then inhibit a broad range of pro-inflammatory 
mediators with activities in vitro and in preclinical models 
of asthma, lung neutrophilia, arthritis, inflammatory bowel 
Fig. 3  Effects of apremilast 
in the dinitrochlorobenzene 
(DNCB) (a) and fluorescein iso-
thiocyanate (FITC) (b) mouse 
models of dermatitis. Data are 
expressed as the mean ± stand-
ard error of the mean. Sensitiza-
tion to either DNCB or FITC 
(applied to the flanks) occurred 
on days 0 and 5. All animals 
received the DNCB or FITC 
antigen, including vehicle. Both 
ears were challenged with either 
DNCB or FITC on days 10, 11, 
and 12. Ear thickness was meas-
ured on each day. *P < 0.05 vs. 
vehicle using one-way analysis 
of variance followed by Tukey’s 
test for pairwise comparisons
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disease, multiple sclerosis, osteoporosis, and other condi-
tions [22–24, 26, 27]. In our study, we found increased levels 
of PDE4 isoforms in skin from patients with AD. Further-
more, we also found that apremilast normalized the altered 
expression of several pro-inflammatory mediators such as 
IL-12/IL-23p40, IL-31, alarmins, and SPRR1 in IL-4- and 
IL-17-stimulated HEKa cells. These results are consistent 
with an early study that demonstrated PDE activity was 
increased in mononuclear leukocytes from patients with 
AD [21].
The cytokine IL-31 is related to cutaneous lymphocyte-
associated antigen positive (CLA+) T cells and is consid-
ered a relevant target for treatment of pruritus [41, 42]. The 
ability of apremilast, a selective PDE4 inhibitor, to regulate 
IL-31 production in IL-4- and IL-17-stimulated keratino-
cytes further supports the hypothesis that normalization of 
PDE4/cAMP activity may be therapeutically beneficial for 
patients with AD.
Based on these preclinical observations, a phase  II, 
double-blind, placebo-controlled trial evaluating apremi-
last efficacy, safety, and pharmacodynamics in adults with 
moderate to severe AD was conducted (ClinicalTrials.gov 
identifier NCT02087943) [43]. Patients were randomized to 
apremilast 30 mg twice daily, apremilast 40 mg twice daily, 
or placebo for 12 weeks and then re-randomized to double-
blind treatment with apremilast 30 or 40 mg twice daily 
through Week 24 (patients initially randomized to apremi-
last continued their assigned dose). Patients who received 
apremilast 40 mg twice daily demonstrated significantly 
greater improvement from baseline on the primary endpoint, 
percentage change from baseline on the Eczema Area and 
Severity Index score at Week 12, than with placebo (mean 
[standard deviation {SD}] 31.6% [44.6] vs. − 11.0% [71.2], 
P < 0.04; effect size [95% confidence interval {CI} −20.6 
[− 39.7 to − 1.5]), and a trend was observed for greater 
improvement with apremilast 30 mg twice daily versus pla-
cebo (mean [SD] − 26.0% [40.1]; effect size [95% CI] 15.0 
[− 34.5 to 4.5], P = not significant). There were no statisti-
cally significant differences in the proportion of patients who 
achieved static Physician’s Global Assessment–Acute signs 
(sPGA-A) response at Week 12 with apremilast 40 mg twice 
daily (14.3% [9/63]) or apremilast 30 mg twice daily (3.4% 
[2/58]) versus placebo (6.3% [4/64]) (effect sizes [95% CIs]: 
8.0 [− 2.3 to 18.2] and − 2.7 [− 10.2 to 4.8], respectively). 
Adverse events, including cellulitis, were more frequent with 
apremilast 40 mg twice daily. An independent safety moni-
toring committee and an external data monitoring committee 
recommended that the apremilast 40 mg twice daily dose be 
discontinued and patients reassigned to apremilast 30 mg 
twice daily [43].
Our preclinical results support previous studies and sug-
gest that apremilast is an effective inhibitor of the Th17 
Fig. 4  Effects of apremilast (APR) on cytokine protein levels in the 
dinitrochlorobenzene (DNCB) mouse model of atopic dermatitis. 
Protein levels of interleukin (IL)-4, IL-10, IL-13, IL-17A, and IL-
12/23p40 were measured in the inflamed ear subsequent to DNCB 
challenge using the Luminex assay. Data are expressed as the mean ± 
standard error of the mean. DEX dexamethasone, *P < 0.05 vs. vehi-
cle using one-way analysis of variance
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pathway in keratinocytes. In the phase II study of apremilast 
in patients with moderate to severe AD (NCT02087943), 
Th17 (IL-17A, IL-12B/IL-12/23p40) and Th17/Th22-asso-
ciated markers (IL-22, S100A7/S100A8, S100A12) were 
significantly reduced with apremilast 40 mg twice daily, with 
K16 mRNA showing the highest, most significant decreases 
(P < 0.05 for all). Reductions were also observed in Th2-
associated cytokines (IL-13, IL-31, CCL17) in the apremi-
last 40 mg twice daily and placebo groups. There were no 
significant reductions in tissue mRNA in patients treated 
with apremilast 30 mg twice daily. IL-17 has been shown to 
play an important role in the pathogenesis of different AD 
phenotypes and the regulation of the Th2 response [44, 45]. 
However, these pharmacological activities alone may not 
be sufficient for apremilast to demonstrate clinical efficacy 
in AD, as efficacy was only modest with the 40 mg twice 
daily dose and not statistically significant different from pla-
cebo with the 30 mg twice daily dose. Nonetheless, given 
the efficacy of the topical PDE4 inhibitor crisaborole, these 
results demonstrate direct effects of PDE4 inhibition on skin 
keratinocytes and gene expression, particularly those in the 
Th17 pathway.
5  Conclusion
We have shown that all PDE4 isoforms are up-regulated in 
AD skin and that inhibiting PDE activity normalizes inflam-
matory cytokines and reduces dermatitis in mouse models. 
These data provide novel insights into the dysregulation of 
PDE4 expression in inflammatory skin from AD patients, 
and highlight the potential direct effects and limitations of 
PDE4 inhibition on keratinocyte responses within this dis-
ease context.
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